This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (48)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Mortimer B. Lipsett, MD

JAMA. 1982;248(8):941-942.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

PHYSICIANS and members of the public understand that each new drug must, at some point, be given to humans for the first time without confident knowledge of its effects and toxic potential. Although the ethics and constraints necessary for this testing have been discussed widely, there has been little attention given specifically to the first trials of new cancer chemotherapeutic agents (phase I trials). However, new cancer chemotherapeutic agents cannot be treated simply as new drugs; their toxic effects are often so much greater than those of other drugs that the clinical investigator must weigh many conflicting arguments to justify the trial. Referring physicians, in their role as advisors, are often called on to explain the trials and to counsel patients who may enter them. Thus, they should have full appreciation of the nature and ethics of such trials.

A phase I clinical trial in patients with cancer does not . . . [Full Text PDF of this Article]

Author Affiliations
From The Clinical Center, National Institutes of Health, Bethesda, Md.

Footnotes
Reprint requests to Bldg 31, 2C-03, National Institutes of Health, Bethesda, MD 20205 (Dr Lipsett).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?